Clinical Trials Browser

Phase 2 × pyrotinib × Thoracic × Clear all

NCT05751018 2025-12-02

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT02834936 2025-08-28

A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation

Phase 2 Completed

Non Small Cell Lung

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04144569 2024-09-19

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

Phase 2 Recruiting

HER2 Insertion Mutation Positive Advanced NSCLC

NCT06185400 2023-12-29

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04063462 2019-08-21

Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02535507 2015-08-28

Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung